Hypothermia Risk With Continuous Renal Replacement Therapy
NCT ID: NCT03973814
Last Updated: 2023-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2022-08-01
2023-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The novel TherMax blood warmer for the newly introduced PrisMax System heats blood and replacement solutions via a dry heat plate system. In contrast, the PRISMAFLO IIS Blood Warmer for PRISMAFLEX System uses an electric heating sleeve on a standard CRRT filter set.
Data on adverse events (AE) during continuous renal replacement therapy (CRRT) has been studied and one of the most common AE was hypothermia, reported in 44% of all cases.
The present study aims at testing if the TherMax blood warmer is more accurate and reliable in reaching and maintaining chosen target temperature during CRRT as compared to the blood warmer used for the PrismaFlex system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
Moreover, we will use historic data on the previous blood warmer for the Prismaflex device to assess temperature changes.
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prior to Thermax Warming
Baseline temperature
Thermax Blood Warmer
Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
During warming
Temperature during Thermax warming
Thermax Blood Warmer
Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
Post warming
Temperature after cessation of Thermax warming
Thermax Blood Warmer
Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thermax Blood Warmer
Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Skane University Hospital
OTHER
Karolinska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Max Bell
MD, PhD, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Max Bell, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Karolinska University Hospital
Marcus Broman, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Skane University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BxIIRgrant
Identifier Type: -
Identifier Source: org_study_id